Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, July 21, 2023

Finger prick test detects blood-based biomarkers of Alzheimer’s disease

With your dementia risk from your stroke you need to have a serious discussion with your doctor on how to prevent dementia once biomarkers are identified. 

Your risk of dementia, has your doctor told you of this?  Your doctor is responsible for preventing this!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

 

Finger prick test detects blood-based biomarkers of Alzheimer’s disease

Key takeaways:

  • Researchers collected venous and finger prick blood samples from memory clinic patients and tested for biomarkers of Alzheimer’s disease.
  • Several biomarkers were detected in the finger prick samples.

A finger prick test measured blood-based biomarkers of Alzheimer’s disease and has potential to increase accessibility of testing, according to research at the Alzheimer’s Association International Conference.

“Currently, use of Alzheimer’s blood tests is limited by the need to visit a clinic, administration by trained personnel, and strict time-limited and temperature-dependent delivery and storage procedures,” Hanna Huber, PhD, of the Institute of Neuroscience and Physiology at the University of Gothenburg in Sweden, said in a related release.

diabetes
According to recent research out of Sweden, a provisional finger-prick blood test may increase accessibility and provide an accurate indicator of Alzheimer’s disease. Image: Adobe Stock

Huber and colleagues initiated a pilot study to determine the capability of capillary dry blood spot (DBS) and venous DBS to measure specific biomarkers of neurodegeneration: neurofilament light (NfL), glial fibrillary acidic protein (GFAP) and phosphorylated tau (p-tau181 and p-tau217).

They collected venous and finger prick blood samples, EDTA plasma and neuropsychological measures from 43 memory clinic participants at ACE Alzheimer Center Barcelona and also examined cerebrospinal fluid biomarkers in 23 of those patients.

Researchers prepared 65 L of venous and capillary blood on DBS cards (Noviplex), which were shipped overnight without temperature control or cooling, to Gothenburg, Sweden. Dried blood samples were extracted from the cards, and NfL, GFAP and p-tau181 were measured.

Huber and colleagues used Pearson correlation for analysis of the DBS samples and EDTA plasma.

According to results, capillary DBS GFAP (r = 0.6773; P < .0001) and NfL levels (r = 0.4593; P = .0022) correlated with their counterparts in EDTA plasma. Similarly, venous DBS GFAP (r = 0.7624; P < .0001), NfL (r = 0.6798; P < .0001) and p-tau181 (r = 0.577; P < .0004) significantly correlated with EDTA plasma.

Additionally, both capillary and venous DBS GFAP correlated with amyloid status (r = 0.4305/r = 0.4223; P < .05) and venous DBS NfL and p-tau181 correlated with Mini-Mental State Examination and Clinical Dementia Rating assessments, as well as amyloid (all P < .05).

“A method that allows blood collection at home and that is simple enough to be performed independently, or by caregivers, would increase accessibility of these tests,” Huber said in the release. “It would result in improved early diagnosis and better monitoring of patients considered ‘at risk’ or those who are receiving approved therapies.”

Reference:

No comments:

Post a Comment